has come and gone and the results were fairly clear: Most retailers continue to deal with the ill effects of a still-sluggish economic environment. Although there were a few that persevered and were able to post better-than-expected results, the majority operating in this space continued to struggle on a year-over-year basis.
The Federal Reserve
is close to ending its massive bond buying program. The next step is to normalize interest rates. But what is normal?
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc.
(PFE), Merck & Co.
(MRK), Valeant Pharmaceuticals International Inc.
(VRX), and Allergan Inc.
Cloud-based electronic health records
have emerged as a popular choice among practitioners. Should investors
get behind this technology
or is this merely the latest fleeting craze?
The June-quarter earnings season is winding to a close, and it has certainly been a mixed bag for the restaurant industry
. We take a look at some of the quarterly numbers and trends effecting results at this time.
a leading provider of 3D printing centric design-to-manufacturing solutions, has given investors mind-blowing returns over the past few years. From a low of $1.30 in 2009, the shares rose to a high of $97.30 in the beginning of this year. The company has seen staggering revenue growth over the past few years, and net profit has grown at an even more rapid rate. However, since reaching that apex, the shares have declined precipitously.
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc
., Merck & Co
., Eli Lilly & Co
., Bristol-Myers Squibb
, Actavis plc
., and Novartis
It has been a long time in coming, but initial large-scale overseas liquefied natural gas
(LNG) shipments from the United States are set to begin in late 2015.
Do you have questions about the new valueline.com? Most questions can be answered by visiting our Help page and reviewing our FAQs. Should you still have questions, please contact a dedicated representative at 1-800-VALUELINE (1-800-825-8354). Reps are available 8am-7pm (ET) Monday - Friday. Additionally, visit valuelinepro.com to view a complete schedule of training webinars.
Giant cable companies
are consolidating and seeing their revenues and profits expand, but customer satisfaction is low leading to those bent on disruption making headway in the video distribution business, especially in the younger demographic.